Effect of a vaccine to prevent serogroup A N meningitidis epidemics in Africa

Lancet Infect Dis. 2017 Aug;17(8):789-790. doi: 10.1016/S1473-3099(17)30300-6. Epub 2017 May 22.

Authors

Sarah A Meyer¹, Ryan T Novak²

Affiliations

¹ Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. Electronic address: vif6@cdc.gov.
² Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

No abstract available

Publication types

Comment

MeSH terms

Africa
Epidemics
Humans
Meningitis, Meningococcal / epidemiology
Meningococcal Vaccines
Neisseria meningitidis / immunology*
Serogroup*
Vaccines

Substances

Meningococcal Vaccines
Vaccines

Grants and funding

CC999999/Intramural CDC HHS/United States